EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy

Arti Dhar, Jegadheeswari Venkadakrishnan, Utsa Roy, Sahithi Vedam, Nikita Lalwani, Kenneth S Ramos, Tej K Pandita, Audesh Bhat iD

Therapeutic Advances in Cardiovascular Disease · 2023-01 · 17

DOI: 10.1177/17539447231210170 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 09.12.2023. Verfasst von Arti Dhar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Diabetes Mellitus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic cardiomyopathy (DCM) is characterized by structural and functional abnormalities in the myocardium affecting people with diabetes. Treatment of DCM focuses on glucose control, blood pressure management, lipid-lowering, and lifestyle changes. Due to limited therapeutic options, DCM remains a significant cause of morbidity and mortality in patients with diabetes, thus emphasizing the need to develop new therapeutic strategies. Ongoing research is aimed at understanding the underlying molecular mechanism(s) involved in the development and progression of DCM, including oxidative stress, inflammation, and metabolic dysregulation. The goal is to develope innovative pharmaceutical therapeutics, offering significant improvements in the clinical management of DCM. Some of these approaches include the effective targeting of impaired insulin signaling, cardiac stiffness, glucotoxicity, lipotoxicity, inflammation, oxidative stress, cardiac hypertrophy, and fibrosis. This review focuses on the latest developments in understanding the underlying causes of DCM and the therapeutic landscape of DCM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesDiabetes MellitusHumansMyocardiumHeartSignal TransductionInflammation

Stichwörter der Autor:innen

cardiovascular diseasesdiabetic cardiomyopathyfibrosisglucotoxicityinflammationinsulin signalinglipotoxicityoxidative stresstype 2 diabetes

Autor:innen und Institutionen

  • Department of Pharmacy, Birla Institute of Technology and Science Pilani, Hyderabad, Telangana, India.
  • Center for Genomics and Precision Medicine, Texas A&M College of Medicine, Houston, TX 77030, USA.
  • Centre for Molecular Biology, Central University of Jammu, Samba, Jammu and Kashmir (UT) 184311, India.

ORCID-Profile: Audesh Bhat

Zitieren

APA

Dhar, A., Venkadakrishnan, J., Roy, U., Vedam, S., Lalwani, N., Ramos, K. S., Pandita, T. K., & Bhat, A. (2023). A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. Therapeutic Advances in Cardiovascular Disease, 17. https://doi.org/10.1177/17539447231210170

Vancouver

Dhar A, Venkadakrishnan J, Roy U, Vedam S, Lalwani N, Ramos KS, et al. A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. Therapeutic Advances in Cardiovascular Disease. 2023;17. doi:10.1177/17539447231210170

BibTeX
@article{Dhar2023,
  author = {Dhar, Arti and Venkadakrishnan, Jegadheeswari and Roy, Utsa and Vedam, Sahithi and Lalwani, Nikita and Ramos, Kenneth S and Pandita, Tej K and Bhat, Audesh},
  title = {A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2023},
  volume = {17},
  doi = {10.1177/17539447231210170}
}
Kostenlos starten →